Skip to main navigation Skip to search Skip to main content

Revisiting Injectable Estrogen Dosing Recommendations for Gender-Affirming Hormone Therapy

  • Micol S. Rothman
  • , Ole Petter R. Hamnvik
  • , Caroline Davidge-Pitts
  • , Joshua D. Safer
  • , Danit Ariel
  • , Vin Tangpricha
  • , Jessica Abramowitz
  • , Kyaw Soe
  • , Jenna Sarvaideo
  • , Carly Kelley
  • , Michael S. Irwig
  • , Sean J. Iwamoto

Research output: Contribution to journal › Review article › peer-review

5 Scopus citations

Abstract

Injectable estrogens are options for gender-affirming hormone therapy per guidelines, which suggest intramuscular dosages of 5-30 mg every 2 weeks or 2-10 mg weekly with estradiol cypionate or valerate interchangeably. Data among transgender and gender-diverse patients are limited due to local unavailability and concerns around laboratory assay variability and estradiol (E2) level fluctuation. We note a concerning trend where patients are prescribed high-dose injections based on the guidelines leading to serum E2 levels well above the range recommended in the same guidelines. Our review indicates that 5 mg weekly or lower should be prescribed when initiating injectable estrogens to avoid supraphysiologic E2 levels.

Original languageEnglish
Pages (from-to)463-465
Number of pages3
JournalTransgender Health
Volume9
Issue number6
DOIs
StatePublished - 1 Dec 2024

Keywords

  • estradiol cypionate
  • estradiol level
  • estradiol valerate
  • gender-affirming hormone therapy
  • injectable estrogen dosing
  • transgender

Fingerprint

Dive into the research topics of 'Revisiting Injectable Estrogen Dosing Recommendations for Gender-Affirming Hormone Therapy'. Together they form a unique fingerprint.

Cite this